Semantic Scholar uses AI to extract papers important to this topic.
In France, more than 2.5 million patients are currently treated with levothyroxine, mainly as the marketed product Levothyrox… Expand I read with interest the article published in Clinical Pharmacokinetics by Didier Concordet and colleagues , who reported an… Expand In a recent ‘Current Opinion’ paper in Clinical Pharmacokinetics, Concordet et al.  postulated that the withinsubject variance… Expand We are pleased to respond to the letter of Coste at al.  as follows. Nowhere in our article is any claim made to analyse the… Expand At the request of French Regulatory Authorities, a new formulation of Levothyrox ® was licensed in France in 2017, with the… Expand We are pleased to respond to the letter of Munafo et al.  as follows: in our levothyroxine article , we concluded that “a… Expand Since patients may report spontaneously adverse events associated with their medications, such notifications are constantly on… Expand Objectifs Le Levothyrox®, prescrit en France a plus de trois millions de patients atteints de pathologie thyroidienne, a fait l… Expand Abstract Objective: Small levothyroxine (L-T4) dose changes can lead to significant clinical effects. To ensure thyroid hormone… Expand A 24-year-old adult with a Down syndrome was admitted in December 2006 at the Moutiers hospital in the French Alps for an acute… Expand